Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1428
- Registration Number
- NCT04537923
- Locations
- 🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Metabolic Research Institute, Inc., West Palm Beach, Florida, United States
🇺🇸J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain
- Conditions
- Chronic Low-back Pain
- Interventions
- Drug: LY3016859Drug: Placebo
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 149
- Registration Number
- NCT04529096
- Locations
- 🇺🇸
Northwest Clinical Research Center, Bellevue, Washington, United States
🇺🇸Synexus - US, Murray, Utah, United States
🇺🇸Great Lakes Research Group, Inc., Bay City, Michigan, United States
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- Conditions
- Juvenile Psoriatic ArthritisEnthesitis Related Arthritis
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT04527380
- Locations
- 🇬🇧
Sheffield Children's Hospital, Sheffield, United Kingdom
🇬🇧Alder Hey Children's Hospital, Liverpool, England, United Kingdom
🇬🇧Oxford University Hospitals - Nuffield Orthopaedic Centre, Oxford, Oxfordshire, United Kingdom
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
- Conditions
- Any Solid TumorGliomaCholangiocarcinomaChondrosarcoma
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT04521686
- Locations
- 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
- Conditions
- Nakajo-Nishimura SyndromeChronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature SyndromeSTING-Associated Vasculopathy With Onset in InfancyAicardi Goutieres Syndrome
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT04517253
- Locations
- 🇯🇵
Tokyo Medical And Dental University Medical Hospital, Bunkyō, Tokyo, Japan
🇯🇵Hiroshima University Hospital, Hiroshima, Japan
🇯🇵Wakayama Medical University Hospital, Wakayama, Japan
A Study of LY3493269 in Participants With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT04515576
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study of LY3451838 in Participants With Migraine
- Conditions
- Migraine
- Interventions
- Drug: LY3451838Drug: Placebo
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT04498910
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Clinvest Research LLC, Springfield, Missouri, United States
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
- Conditions
- COVID-19SARS-CoV2
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1180
- Registration Number
- NCT04497987
- Locations
- 🇺🇸
Care Access, Jackson, Mississippi, United States
🇺🇸Care Access Research LLC, Huntington Beach, California, United States
🇺🇸Valley Medical Primary Care, Centerville, Ohio, United States
A Safety Study of LY3493269 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: LY3493269
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT04498390
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Ramucirumab (LY3009806) in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: Ramucirumab - SCDrug: Placebo - IVDrug: Ramucirumab - IVDrug: Placebo - SC
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT04495478
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States